Fares Zahir, a Malaysian, was appointed to the Board on 16 December 2011.
He holds a Bachelor of Economics degree in Actuarial Studies from Macquarie University in Australia a Master of Applied Science in Operations Research from University Technology Sydney. He is also a Chartered Financial Analyst (CFA) and an Associate of the Society of Actuaries (ASA) of North America.
Fares Zahir has 20 years of experience in the field of investment in public and private equities. He was previously with Khazanah Nasional Berhad, where he headed the Life Sciences Unit that formulates investment strategies, and undertakes and monitors the organisation’s Life Science investments, and also headed Khazanah’s Research Unit that undertakes research work in the areas of financial capital markets, industrial organisation and economics.
Encik Fares Zahir is the co-founder of Xeraya Capital Sdn Bhd and was appointed as its Chief Executive Officer in January 2012. He is Co-Chairman of the Malaysian Life Sciences Capital Fund (MLSCF), a fund that is globally recognized in the biogreentech space. He is also a Board Member of the Malaysian Technology Development Corporation Sdn Bhd and Spring Hill Bioventures Sdn Bhd.
Encik Fares Zahir was a Director, Investment Research at UBS Investment Bank where he was a key member of their top rated Malaysian equity research team. Prior to that, he was Fund Manager with the Schroder Group (also a JV company of the PNB Group) where he managed the Schroder Group’s institutional clients’ portfolios after serving as an investment analyst making investment recommendations to the Schroder Group’s portfolio managers worldwide. Encik Fares Zahir started his career in the actuarial department of American International Assurance Co. Ltd in Kuala Lumpur.